Literature DB >> 18452066

Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha.

Dushyant Verma, Hagop Kantarjian, Nitin Jain, Jorge Cortes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18452066     DOI： 10.1080/10428190802043903

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  8 in total

1.  Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia.

Authors:  Naoto Takahashi; Taiichi Kyo; Yasuhiro Maeda; Takashi Sugihara; Kensuke Usuki; Tatsuya Kawaguchi; Noriko Usui; Shinichiro Okamoto; Yokiko Ohe; Shigeki Ohtake; Kunio Kitamura; Masahide Yamamoto; Hirofumi Teshima; Toshiko Motoji; Toshiharu Tamaki; Kenichi Sawada; Kazuma Ohyashiki
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

2.  Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia.

Authors:  D Sanford; R Kyle; A Lazo-Langner; A Xenocostas; I Chin-Yee; K Howson-Jan; C Hsia
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

Review 3.  Molecular monitoring.

Authors:  Simona Soverini; Gianantonio Rosti; Michele Baccarani; Giovanni Martinelli
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

4.  NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.

Authors:  Susan O'Brien; Ellin Berman; Joseph O Moore; Javier Pinilla-Ibarz; Jerald P Radich; Paul J Shami; B Douglas Smith; David S Snyder; Hema M Sundar; Moshe Talpaz; Meir Wetzler
Journal:  J Natl Compr Canc Netw       Date:  2011-02       Impact factor: 11.908

5.  Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.

Authors:  Tom Lenaerts; Jorge M Pacheco; Arne Traulsen; David Dingli
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

Review 6.  Minimal Residual Disease Eradication in CML: Does It Really Matter?

Authors:  Srinivas K Tantravahi; Raga S Guthula; Thomas O'Hare; Michael W Deininger
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

Review 7.  Imatinib and beyond--exploring the full potential of targeted therapy for CML.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes
Journal:  Nat Rev Clin Oncol       Date:  2009-08-04       Impact factor: 66.675

8.  Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy.

Authors:  Jean-Claude Chomel; Ali G Turhan
Journal:  Oncotarget       Date:  2011-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.